Stay at the forefront of drug discovery and therapeutic development with Drug Target Review. Dive into the latest research, industry analysis and technological advancements. Connect with world-renowned scientists and explore peer-reviewed articles, webinars, and more.

Jan 16, 2025 · Streamlining macrocyclic therapeutic development. Platforms such as PeptiDream’s drug discovery platform system 17 have facilitated easier synthesis and screening of macrocyclic peptide libraries for lead compounds (eg, the PD-L1 macrocycle from Figure 1). Another approach to macrocyclic library design is to generate pools of peptidic scaffolds that are designed to possess qualities such as ...

Feb 13, 2024 · Co-corresponding author Dr David Leib, chair and professor of microbiology and immunology at Geisel, explained: “Despite three decades of trying, the scientific community has been unable to develop an effective vaccine against herpes, and I think the main issue has been that we haven’t fully understood what we need, in terms of antibodies and their specific functions, to protect against ...

Aug 28, 2024 · Cliff Brass is an expert in clinical development with special expertise in liver disease and over 25 years of experience in pharma. Most recently Dr Brass was Vice President, Head of Clinical Sciences for Hepatology, Gastroenterology and Transplantation in Global Drug Development at Novartis.

Jan 23, 2024 · Dr Espen Basmo Ellingsen. University of Oslo . Dr Ellingsen is a Medical Doctor and holds a PhD in cancer immunology from the University of Oslo. Background in translational research from the Institute for Cancer Research at Oslo University Hospital, focusing on therapeutic cancer vaccination, induced immune responses, and their impact on the tumor microenvironment.

Sep 19, 2024 · Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam. Following successful interactions at the End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration (FDA) earlier this year we now look forward to the interactions with European drug regulatory authorities in the autumn for the start of a ...

Dec 12, 2024 · Novartis has partnered with PTC Therapeutics to develop and commercialise PTC518, a promising small molecule therapy targeting the root cause of Huntington’s disease.. In a move that could significantly impact the treatment landscape for Huntington’s disease, Novartis has secured an exclusive licensing agreement with …

Aug 6, 2024 · Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers that will impact ADCs’ ability to make the shift from oncology to a broader ...

Oct 4, 2023 · The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Second-generation ADCs, with payloads like the tubulin polymerisation inhibitors maytansinoids and auristatins, stood out with their antiproliferative activity against tumour cells but also came with severe side effects.

Dec 20, 2024 · article Scientific workflow for hypothesis testing in drug discovery: Part 2 of 3. 14 January 2025 | By Dr Raminderal Singh (Hitchhikers AI and 20/15 Visioneers, Nina Truter. In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and …